CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer.
Autorzy:
Cornelison R; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. Biswas K; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. Llaneza DC; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. Harris AR; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. Sosale NG; Department of Chemical Engineering, University of Virginia, Charlottesville, VA 22908, USA. Lazzara MJ; Department of Chemical Engineering, University of Virginia, Charlottesville, VA 22908, USA. LandenCN; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Oct 09; Vol. 13 (20). Date of Electronic Publication: 2021 Oct 09.
A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer.
Autorzy:
Perez SM; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA. Dimastromatteo J; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA.; ZielBio, Inc., Charlottesville, VA 22903, USA. LandenCN Jr; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Virginia, Charlottesville, VA 22908, USA. Kelly KA; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA.; ZielBio, Inc., Charlottesville, VA 22903, USA.
Pokaż więcej
Źródło:
Cells [Cells] 2021 Aug 27; Vol. 10 (9). Date of Electronic Publication: 2021 Aug 27.
Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer.
Autorzy:
Lazo JS; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.; KeViRx, Inc., Charlottesville, VA 22904, USA. Sharlow ER; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.; KeViRx, Inc., Charlottesville, VA 22904, USA. Cornelison R; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA.; KeViRx, Inc., Charlottesville, VA 22904, USA. Hart DJ; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA. Llaneza DC; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA. Mendelson AJ; Department of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA. Rastelli EJ; Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA. Tasker NR; Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA. LandenCN Jr; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. Wipf P; Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Pokaż więcej
Źródło:
Biomolecules [Biomolecules] 2021 Jun 30; Vol. 11 (7). Date of Electronic Publication: 2021 Jun 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Autorzy:
Byun JM; Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, College of Medicine, Busan, South Korea.; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea. Lee DS; Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, College of Medicine, Busan, South Korea.; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea. LandenCN; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. Kim DH; Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, College of Medicine, Busan, South Korea.; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea. Kim YN; Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, College of Medicine, Busan, South Korea.; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea. Lee KB; Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, College of Medicine, Busan, South Korea.; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea. Sung MS; Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, College of Medicine, Busan, South Korea.; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea. Park SG; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea.; Department of Microbiology, Inje University, College of Medicine, Busan, South Korea. Jeong DH; Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, College of Medicine, Busan, South Korea.; College of Medicine, Paik Institute for Clinical Research, Inje University, Busan, South Korea.
Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer.
Autorzy:
Emmings E; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Heath, University of Minnesota, Minneapolis, MN 55455, USA. . Mullany S; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Heath, University of Minnesota, Minneapolis, MN 55455, USA. . Chang Z; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Heath, University of Minnesota, Minneapolis, MN 55455, USA. . LandenCN Jr; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. . Linder S; Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institute, S-171 76 Stockholm, Sweden. .; Department of Medical Health Sciences (IMH), Linköping University, S-751 85 Linköping, Sweden. . Bazzaro M; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Heath, University of Minnesota, Minneapolis, MN 55455, USA. .
Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.
Autorzy:
Cornelison R; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. . Llaneza DC; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. . LandenCN; Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA 22908, USA. .
The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.
Autorzy:
Dobbin ZC; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Wallace Tumor Institute, 1824 6th Avenue South, Birmingham, AL 35233, USA. . LandenCN
Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane.
Autorzy:
Chen H; Department of Biology, University of Alabama at Birmingham, CH175, 1300 University Boulevard, Birmingham, AL 35294-1170, USA. LandenCN Li Y Alvarez RD Tollefsbol TO
Pokaż więcej
Źródło:
Journal of oncology [J Oncol] 2013; Vol. 2013, pp. 872957. Date of Electronic Publication: 2013 Feb 17.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
